Marcia Pomplun

996 total citations
18 papers, 838 citations indexed

About

Marcia Pomplun is a scholar working on Molecular Biology, Oncology and Biochemistry. According to data from OpenAlex, Marcia Pomplun has authored 18 papers receiving a total of 838 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Oncology and 8 papers in Biochemistry. Recurrent topics in Marcia Pomplun's work include Amino Acid Enzymes and Metabolism (8 papers), Cancer Treatment and Pharmacology (5 papers) and Polyamine Metabolism and Applications (5 papers). Marcia Pomplun is often cited by papers focused on Amino Acid Enzymes and Metabolism (8 papers), Cancer Treatment and Pharmacology (5 papers) and Polyamine Metabolism and Applications (5 papers). Marcia Pomplun collaborates with scholars based in United States and Spain. Marcia Pomplun's co-authors include George Wilding, Dona Alberti, Howard H. Bailey, K D Tutsch, Kendra D. Tutsch, Chris Feierabend, R Z Arzoomanian, Ríona Mulcahy, Gregory H. Ripple and Ajit Kumar Verma and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Marcia Pomplun

18 papers receiving 815 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marcia Pomplun United States 14 497 220 161 115 82 18 838
Pamela K. Smitherman United States 18 652 1.3× 327 1.5× 169 1.0× 73 0.6× 67 0.8× 20 1.0k
Wolfgang A. Schmalix Germany 20 464 0.9× 172 0.8× 123 0.8× 275 2.4× 54 0.7× 35 1.0k
Martin Wurm Austria 12 364 0.7× 233 1.1× 111 0.7× 85 0.7× 45 0.5× 20 861
Katriina Kahlos Finland 19 649 1.3× 151 0.7× 136 0.8× 193 1.7× 78 1.0× 24 1.1k
Mitsunori Okabe Japan 9 409 0.8× 556 2.5× 78 0.5× 81 0.7× 101 1.2× 9 958
Ruilan Yan United States 13 725 1.5× 197 0.9× 49 0.3× 166 1.4× 37 0.5× 19 1.1k
C. H. Baker United States 13 751 1.5× 172 0.8× 92 0.6× 40 0.3× 88 1.1× 37 1.1k
Uttam Pati India 23 641 1.3× 251 1.1× 32 0.2× 229 2.0× 96 1.2× 40 1.1k
Saifuddin Sheikh India 16 476 1.0× 143 0.7× 42 0.3× 96 0.8× 35 0.4× 35 792
Jian Cui China 21 940 1.9× 176 0.8× 56 0.3× 277 2.4× 204 2.5× 39 1.3k

Countries citing papers authored by Marcia Pomplun

Since Specialization
Citations

This map shows the geographic impact of Marcia Pomplun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcia Pomplun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcia Pomplun more than expected).

Fields of papers citing papers by Marcia Pomplun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcia Pomplun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcia Pomplun. The network helps show where Marcia Pomplun may publish in the future.

Co-authorship network of co-authors of Marcia Pomplun

This figure shows the co-authorship network connecting the top 25 collaborators of Marcia Pomplun. A scholar is included among the top collaborators of Marcia Pomplun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcia Pomplun. Marcia Pomplun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Kolesar, Jill, Marcia Pomplun, KyungMann Kim, et al.. (2014). Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. Journal of Oncology Pharmacy Practice. 21(2). 128–131. 1 indexed citations
2.
Kolesar, Jill, Richard C. Brundage, Marcia Pomplun, et al.. (2010). Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients. Cancer Chemotherapy and Pharmacology. 67(2). 393–400. 45 indexed citations
3.
Kolesar, Jill, Marcia Pomplun, Helen Krontiras, et al.. (2010). A Pilot, First-in-Human, Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers. Cancer Prevention Research. 3(12). 1565–1570. 30 indexed citations
4.
Vanderloo, Joshua P., Marcia Pomplun, Lee C. Vermeulen, & Jill Kolesar. (2010). Stability of unused reconstituted bortezomib in original manufacturer vials. Journal of Oncology Pharmacy Practice. 17(4). 400–402. 26 indexed citations
5.
Schelman, William R., Rebecca Marnocha, Fred Lee, et al.. (2008). A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 63(6). 1147–1156. 30 indexed citations
6.
Pomplun, Marcia, Jeremy Johnson, Susan Johnston, & Jill Kolesar. (2007). Stability of a heparin-free 50% ethanol lock solution for central venous catheters. Journal of Oncology Pharmacy Practice. 13(1). 33–37. 6 indexed citations
7.
Wilding, George, David K. King, Kendra D. Tutsch, et al.. (2004). Phase I Trial of the Polyamine Analog N1,N14-Diethylhomospermine (DEHSPM) in Patients with Advanced Solid Tumors. Investigational New Drugs. 22(2). 131–138. 11 indexed citations
8.
Dubey, Sarita, Michael N. Gould, Kendra D. Tutsch, et al.. (2003). Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemotherapy and Pharmacology. 52(5). 361–366. 21 indexed citations
9.
Ripple, Gregory H., Michael N. Gould, Rhoda Arzoomanian, et al.. (2000). Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.. PubMed. 6(2). 390–6. 83 indexed citations
10.
Carbone, Paul P., et al.. (2000). Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine.. PubMed. 6(10). 3850–4. 13 indexed citations
11.
Messing, Edward M., Richard R. Love, K D Tutsch, et al.. (1999). Low-Dose Difluoromethylornithine and Polyamine Levels in Human Prostate Tissue. JNCI Journal of the National Cancer Institute. 91(16). 1416–1417. 15 indexed citations
12.
Carbone, Paul P., Jeffrey A. Douglas, Paul O. Larson, et al.. (1998). Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.. PubMed. 7(10). 907–12. 37 indexed citations
13.
Love, Richard R., Russell F. Jacoby, Michael A. Newton, et al.. (1998). A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.. PubMed. 7(11). 989–92. 44 indexed citations
14.
Hutson, Paul R., Kendra D. Tutsch, Randall Rago, et al.. (1998). Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.. PubMed. 4(6). 1429–36. 9 indexed citations
15.
Ripple, Gregory H., Michael N. Gould, James A. Stewart, et al.. (1998). Phase I clinical trial of perillyl alcohol administered daily.. PubMed. 4(5). 1159–64. 92 indexed citations
16.
Bailey, Howard H., Gregory H. Ripple, K D Tutsch, et al.. (1997). Phase I Study of Continuous-Infusion L-S,R-Buthionine Sulfoximine With Intravenous Melphalan. JNCI Journal of the National Cancer Institute. 89(23). 1789–1796. 139 indexed citations
17.
Bailey, Howard H., Ríona Mulcahy, K D Tutsch, et al.. (1994). Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.. Journal of Clinical Oncology. 12(1). 194–205. 161 indexed citations
18.
Love, Richard R., Paul P. Carbone, Ajit Kumar Verma, et al.. (1993). Randomized Phase I Chemoprevention Dose-Seeking Study of  -Difluoromethylornithine. JNCI Journal of the National Cancer Institute. 85(9). 732–737. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pamela K. Smitherman Breakdown of academic impact, for papers by Wolfgang A. Schmalix Breakdown of academic impact, for papers by Martin Wurm Breakdown of academic impact, for papers by Katriina Kahlos Breakdown of academic impact, for papers by Mitsunori Okabe Breakdown of academic impact, for papers by Ruilan Yan Breakdown of academic impact, for papers by C. H. Baker Breakdown of academic impact, for papers by Uttam Pati Breakdown of academic impact, for papers by Saifuddin Sheikh Breakdown of academic impact, for papers by Jian Cui
Rankless by CCL
2026